Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...

Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...

Johnson & Johnson (J&J) raised its 2024 profit and sales forecasts on October 15, thanks to strong sales of oncology drugs, ...

Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...

Johnson and Johnson reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine ...